A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.

Kennedy, J S; Bymaster, F P; Schuh, L; Calligaro, D O; Nomikos, G; Felder, C C; Bernauer, M; Kinon, B J; Baker, R W; Hay, D; Roth, H J; Dossenbach, M; Kaiser, C; Beasley, C M; Holcombe, J H; Effron, M B; Breier, A

Kennedy, J S; Bymaster, F P; Schuh, L; Calligaro, D O; Nomikos, G; Felder, C C; Bernauer, M; Kinon, B J; Baker, R W; Hay, D; Roth, H J; Dossenbach, M; Kaiser, C; Beasley, C M; Holcombe, J H; Effron, M B; Breier, A.

Affiliation

Kennedy JS; Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

Int J Geriatr Psychiatry ; 16 Suppl 1: S33-61, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11748788

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pirenzepine / Alzheimer Disease Limits: Aged / Animals / Humans Language: En Journal: Int J Geriatr Psychiatry Journal subject: GERIATRIA / PSIQUIATRIA Year: 2001 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links